MNPR Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Monopar Therapeutics's net margin of 12.11%. Monopar Therapeutics's return on equity of -- beat Electromed's return on equity of 15.91%.

Monopar Therapeutics has a consensus price target of $58.69, signalling upside risk potential of 54.38%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 63.21%. Given that Electromed has higher upside potential than Monopar Therapeutics, analysts believe Electromed is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 1.005, which suggesting that the stock is 0.519% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Monopar Therapeutics's net income of -$1.3M is lower than Electromed's net income of $2M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 30.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 3.40x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystems Holdings has a net margin of -- compared to Monopar Therapeutics's net margin of 2.76%. Monopar Therapeutics's return on equity of -- beat InfuSystems Holdings's return on equity of 4.33%.

Monopar Therapeutics has a consensus price target of $58.69, signalling upside risk potential of 54.38%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 183.64%. Given that InfuSystems Holdings has higher upside potential than Monopar Therapeutics, analysts believe InfuSystems Holdings is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 1.005, which suggesting that the stock is 0.519% more volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.898, suggesting its more volatile than the S&P 500 by 89.81%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than InfuSystems Holdings quarterly revenues of $33.8M. Monopar Therapeutics's net income of -$1.3M is lower than InfuSystems Holdings's net income of $933K. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 49.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 0.80x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Monopar Therapeutics's net margin of -18.58%. Monopar Therapeutics's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Monopar Therapeutics has a consensus price target of $58.69, signalling upside risk potential of 54.38%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Monopar Therapeutics has higher upside potential than Retractable Technologies, analysts believe Monopar Therapeutics is more attractive than Retractable Technologies.

Monopar Therapeutics has a beta of 1.005, which suggesting that the stock is 0.519% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Monopar Therapeutics's net income of -$1.3M is higher than Retractable Technologies's net income of -$1.9M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -- compared to Monopar Therapeutics's net margin of -118.53%. Monopar Therapeutics's return on equity of -- beat Stereotaxis's return on equity of -139.2%.

Monopar Therapeutics has a consensus price target of $58.69, signalling upside risk potential of 54.38%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 151.4%. Given that Stereotaxis has higher upside potential than Monopar Therapeutics, analysts believe Stereotaxis is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 1.005, which suggesting that the stock is 0.519% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Stereotaxis quarterly revenues of $6.3M. Monopar Therapeutics's net income of -$1.3M is higher than Stereotaxis's net income of -$7.5M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 5.66x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.